Clinical Trials Browser

Phase 2 × Neuroendocrine Tumors × surufatinib × Clear all

NCT04579679 2025-07-25

Open-Label Surufatinib in European Patients With NET

Phase 2 Terminated

78 enrolled 20 charts

Neuroendocrine Tumors

NCT05165407 2025-03-14

NESSIE

Phase 2 Recruiting

Neuroendocrine Tumors